Holly K. Koblish

ScholarGPS® ID: 73175377594307

Affiliation
Incyte Corporation, Wilmington, Delaware, United States
Affiliation History

Field
Pharmacy and Pharmaceutical Sciences
Discipline
Pharmacology and Toxicology
Top Specialties
Cancer | Neoplasm | Medicinal Chemistry | Cancer Immunotherapy
Metrics Summary
Publication Count
33
Predicted Citations
4,531
Predicted h-index
25
Ranking

Publications and Citation History

Publications based on Top Specialties

Types of Publication

  • Publications
  • Books
  • Patents
  • NIH/NSF
You must register and claim your profile to add or remove publications from it.
... publications
FILTER BY:
Year
Type
Specialty
Affiliations
Access
Co-Authors
Add
Delete
A Humanized Animal Model Predicts Clonal Evolution and Therapeutic Vulnerabilities in Myeloproliferative Neoplasms (journal article)
Celik, Hamza | Krug, Ethan | Zhang, Christine R. | Han, Wentao | Issa, Nancy | Koh, Won Kyun | Bjeije, Hassan | Kukhar, Ostap | Allen, Maggie | Li, Tiandao | ... | Challen, Grant A.
Cancer Discovery, volume 11, issue 12, pages 3126-3141 (2021).
10.1158/2159-8290.CD-20-1652
Cited by (21) | Cite | Source
232 INCB090244, a potent small molecule that inhibits the PD-L1/PD-1 axis and functions similarly to PD-L1 antibodies (journal article)
Rios-Doria, Jonathan | Volgina, Alla | Gokhale, Prafulla | Liu, Hao | Stevens, Christina | Zolotarjova, Nina | DiMatteo, Darlise | Kapilashrami, Kanishk | Behshad, Elham | Thekkat, Pramod | ... | Koblish, Holly
Journal for ImmunoTherapy of Cancer, volume 9, issue Suppl 2, pages A247-A247 (2021).
10.1136/jitc-2021-SITC2021.232
Cited by (1) | Cite | Source
Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor (journal article)
Wu, Liangxing | Zhang, Colin | He, Chunhong | Qian, Dingquan | Lu, Liang | Sun, Yaping | Xu, Meizhong | Zhuo, Jincong | Liu, Phillip C. C. | Klabe, Ronald | ... | Yao, Wenqing
Journal of Medicinal Chemistry, volume 64, issue 15, pages 10666-10679 (2021).
10.1021/acs.jmedchem.1c00713
Cited by (42) | Cite | Source
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity (journal article)
Rios-Doria, Jonathan | Favata, Margaret | Lasky, Kerri | Feldman, Patricia | Lo, Yvonne | Yang, Gengjie | Stevens, Christina | Wen, Xiaoming | Sehra, Sarita | Katiyar, Kamna | ... | Koblish, Holly
Frontiers in Oncology, volume 10 (2020).
10.3389/fonc.2020.598477
Cited by (23) | Cite | Source
Characterization of INCB00928, a Potent and Selective ALK2 Inhibitor for the Treatment of Anemia (journal article)
Chen, Yaoyu | Stubbs, Matthew C. | Pusey, Michelle | Wen, Xiaoming | Collins, Robert J. | Kapilashrami, Kanishk | Rupar, Mark | Thekkat, Pramod | Lin, Luping | Bowman, Kevin | ... | Wee, Susan
Blood, volume 136, issue Supplement 1, pages 52-52 (2020).
10.1182/blood-2020-136138
Cited by (6) | Cite | Source
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models (journal article)
Liu, Phillip C. C. | Koblish, Holly | Wu, Liangxing | Bowman, Kevin | Diamond, Sharon | DiMatteo, Darlise | Zhang, Yue | Hansbury, Michael | Rupar, Mark | Wen, Xiaoming | ... | Hollis, Gregory
PLOS ONE, volume 15, issue 4, pages e0231877- (2020).
10.1371/journal.pone.0231877
Cited by (111) | Cite | Source
Low dose combination therapy for treatment of myeloproliferative neoplasms (patent)
Koblish, Holly | Reuther, Gary
Patent Number: 10596161 (2020)
Cite | Source
Characterization of human cancer xenografts in humanized mice (journal article)
Rios-Doria, Jonathan | Stevens, Christina | Maddage, Christopher | Lasky, Kerri | Koblish, Holly K
Journal for ImmunoTherapy of Cancer, volume 8, issue 1, pages e000416- (2020).
10.1136/jitc-2019-000416
Cited by (37) | Cite | Source
The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN (journal article)
Mazzacurati, Lucia | Collins, Robert J. | Pandey, Garima | Lambert-Showers, Que T. | Amin, Narmin E. | Zhang, Ling | Stubbs, Matthew C. | Epling-Burnette, Pearlie K. | Koblish, Holly K. | Reuther, Gary W.
Blood Advances, volume 3, issue 22, pages 3503-3514 (2019).
10.1182/bloodadvances.2019000260
Cited by (24) | Cite | Source
Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia (journal article)
Sung, Pamela J. | Sugita, Mayumi | Koblish, Holly | Perl, Alexander E. | Carroll, Martin
Blood Advances, volume 3, issue 7, pages 1061-1072 (2019).
10.1182/bloodadvances.2018029850
Cited by (40) | Cite | Source
Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1 (journal article)
Werfel, Thomas A. | Elion, David L. | Rahman, Bushra | Hicks, Donna J. | Sanchez, Violeta | Gonzales-Ericsson, Paula I. | Nixon, Mellissa J. | James, Jamaal L. | Balko, Justin M. | Scherle, Peggy A. | ... | Cook, Rebecca S.
Cancer Research, volume 79, issue 1, pages 171-182 (2019).
10.1158/0008-5472.CAN-18-1106
Cited by (60) | Cite | Source
Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies (journal article)
Koblish, Holly | Li, Yun-long | Shin, Niu | Hall, Leslie | Wang, Qian | Wang, Kathy | Covington, Maryanne | Marando, Cindy | Bowman, Kevin | Boer, Jason | ... | Scherle, Peggy
PLOS ONE, volume 13, issue 6, pages e0199108- (2018).
10.1371/journal.pone.0199108
Cited by (37) | Cite | Source | Open Access
INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology (journal article)
Yue, Eddy W. | Sparks, Richard | Polam, Padmaja | Modi, Dilip | Douty, Brent | Wayland, Brian | Glass, Brian | Takvorian, Amy | Glenn, Joseph | Zhu, Wenyu | ... | Combs, Andrew P.
ACS Medicinal Chemistry Letters, volume 8, issue 5, pages 486-491 (2017).
10.1021/acsmedchemlett.6b00391
Cited by (234) | Cite | Source | Open Access
Pharmacological inactivation of PI3Kδ in the tumor microenvironment enhances efficacy of other immunotherapeutic agents (journal article)
Wang, Liang-Chuan S | Koblish, Holly | Hansbury, Michael | Zhang, Yue | Yang, Gengjie | Burn, Timothy | Waeltz, Paul | Rupar, Mark | Yue, Eddy | Douty, Brent | ... | Scherle, Peggy
Journal for ImmunoTherapy of Cancer, volume 3, issue S2 (2015).
10.1186/2051-1426-3-S2-P377
Cited by (2) | Cite | Source | Open Access
Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment (journal article)
Spranger, Stefani | Koblish, Holly K | Horton, Brendan | Scherle, Peggy A | Newton, Robert | Gajewski, Thomas F
Journal for ImmunoTherapy of Cancer, volume 2, issue 1, pages 3- (2014).
10.1186/2051-1426-2-3
Cited by (459) | Cite | Source | Open Access
A Novel Kinase Inhibitor, INCB28060, Blocks c-MET–Dependent Signaling, Neoplastic Activities, and Cross-Talk with EGFR and HER-3 (journal article)
Liu, Xiangdong | Wang, Qian | Yang, Gengjie | Marando, Cindy | Koblish, Holly K. | Hall, Leslie M. | Fridman, Jordan S. | Behshad, Elham | Wynn, Richard | Li, Yu | ... | Scherle, Peggy A.
Clinical Cancer Research, volume 17, issue 22, pages 7127-7138 (2011).
10.1158/1078-0432.CCR-11-1157
Cited by (207) | Cite | Source | Open Access
Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity (journal article)
Liu, Xiangdong | Shin, Niu | Koblish, Holly K. | Yang, Gengjie | Wang, Qian | Wang, Kathy | Leffet, Lynn | Hansbury, Michael J. | Thomas, Beth | Rupar, Mark | ... | Scherle, Peggy A.
Blood, volume 115, issue 17, pages 3520-3530 (2010).
10.1182/blood-2009-09-246124
Cited by (486) | Cite | Source | Open Access
Hydroxyamidine Inhibitors of Indoleamine-2,3-dioxygenase Potently Suppress Systemic Tryptophan Catabolism and the Growth of IDO-Expressing Tumors (journal article)
Koblish, Holly K. | Hansbury, Michael J. | Bowman, Kevin J. | Yang, Gengjie | Neilan, Claire L. | Haley, Patrick J. | Burn, Timothy C. | Waeltz, Paul | Sparks, Richard B. | Yue, Eddy W. | ... | Fridman, Jordan S.
Molecular Cancer Therapeutics, volume 9, issue 2, pages 489-498 (2010).
10.1158/1535-7163.MCT-09-0628
Cited by (247) | Cite | Source | Open Access
Discovery of Potent Competitive Inhibitors of Indoleamine 2,3-Dioxygenase with in Vivo Pharmacodynamic Activity and Efficacy in a Mouse Melanoma Model (journal article)
Yue, Eddy W. | Douty, Brent | Wayland, Brian | Bower, Michael | Liu, Xiangdong | Leffet, Lynn | Wang, Qian | Bowman, Kevin J. | Hansbury, Michael J. | Liu, Changnian | ... | Combs, Andrew P.
Journal of Medicinal Chemistry, volume 52, issue 23, pages 7364-7367 (2009).
10.1021/jm900518f
Cited by (224) | Cite | Source
Preclinical in vivo characterization of INCB028060, a novel, potent and highly selective c-Met inhibitor (journal article)
Koblish, H. K. | Liu, X. | Hall, L. | Boer, J. | He, C. | Yeleswaram, S. | Newton, R. C. | Vaddi, K. | Yao, W. | Scherle, P. A. | Fridman, J. S.
Journal of Clinical Oncology, volume 26, issue 15_suppl, pages 14561-14561 (2008).
10.1200/jco.2008.26.15_suppl.14561
Cited by (9) | Cite | Source